Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
September 14, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
September 09, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
August 19, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit,...
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
August 12, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
August 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
August 06, 2020 16:05 ET
|
Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...
Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
June 30, 2020 08:25 ET
|
Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a...
Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
June 16, 2020 08:25 ET
|
Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 16, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
March 27, 2020 09:15 ET
|
Monopar Therapeutics Inc.
Initial public offering on Nasdaq Capital Market in December 2019 Orphan Drug Designation from the European Commission for camsirubicin for the treatment of soft tissue sarcoma CHICAGO, March 27,...
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
December 23, 2019 12:30 ET
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...